Skip to content

The weight loss treatment of NAFLD: the relationship between the reduction degree of visceral fat and the improvement of liver fat in NAFLD patients

The weight loss treatment of NAFLD: the relationship between the reduction degree of visceral fat and the improvement of liver fat in NAFLD patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004657
Enrollment
Unknown
Registered
2014-09-21
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

intervention grop:NAFLD basic health education + nutrition diet guid
Control:NAFLD basic health education + nutrition diet guid

Sponsors

Guangzhou First People's Hospital, Guangzhou Nan Sha Center Hospital Affiliated to Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? no alcohol consumption or alcohol dose <70 g/wk for women and <140 g/wk for men; ?With the exception of viral hepatitis, drug-induced liver disease, total parenteral nutrition, and other diseases can lead to fatty liver disease; ?Liver imaging findings the diagnosis of diffuse fatty liver and no other reason can explain; ?Patients with unexplained and persistent increase in serum ALT and (or), AST, GGT of at least 1.5 times the limit of normal; ?body mass Index (BMI) between 25 and 40Kg/?; ?18-65 years of age; ?Signed informed consent and agreed to enter the study.

Exclusion criteria

Exclusion criteria: ?alcohol consumption and alcohol dose >70 g/wk for women and >140 g/wk for men; ?Without the exception of viral hepatitis, drug-induced liver disease, total parenteral nutrition,and other diseases can lead to fatty liver disease; ?patient receiving hepatotoxicand insulin-sensitizing medication; ?Over the past year had bariatricsurgery; ?used weight loss medication or program in the previous 3 months; ?Patients with pregnancy and lactation; ?patients with mental disorder can't cooperate, don't sign the informed consent; ? age 65 years; ?patients with pacemaker or metallic implants and with claustrophobia.

Design outcomes

Primary

MeasureTime frame
visceral fat content;liver fa;

Secondary

MeasureTime frame
weight;waist circumference;abdominal circumference;liver enzyme;serum lipi;

Countries

China

Contacts

Public ContactLin Jia
jialin@medmail.com.cn+86 13925012853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026